@article{oai:nagoya.repo.nii.ac.jp:00024650,
 author = {Ohka, Fumiharu and Yamamichi, Akane and Kurimoto, Michihiro and Motomura, Kazuya and Tanahashi, Kuniaki and Suzuki, Hiromichi and Aoki, Kosuke and Deguchi, Shoichi and Chalise, Lushun and Hirano, Masaki and Kato, Akira and Nishimura, Yusuke and Hara, Masahito and Kato, Yukinari and Wakabayashi, Toshihiko and Natsume, Atsushi},
 issue = {2},
 journal = {Brain Tumor Pathology},
 month = {Apr},
 note = {IDH1 gene mutation has been demonstrated to be an oncogenic driver in a majority of lower-grade gliomas (LGGs). In contrast to other central nervous neoplasms and normal brain tissue without IDH1 mutation, almost 80% of LGGs exhibit IDH1 mutation. Therefore, expeditious detection of IDH1 mutation is useful, not only for intraoperative diagnosis of these gliomas but also for determination of the border between the tumor and normal brain tissue. In this study, we established a rapid genotyping assay with a simple DNA extraction method, involving only incubation of the tumor specimen with Tris–EDTA buffer, which can be easily performed in an operating room. In all 11 tested cases, we could identify the IDH1 status within 90–100 min intraoperatively. In a case of anaplastic astrocytoma, IDH-mutant, we could detect the tumor border by IDH1 profiling. In addition, with this assay, we could detect IDH1 mutation using cell-free tumor DNA derived from cerebrospinal fluid in a case of glioblastoma, IDH-mutant. Considering that clinical trials of mutated IDH1 inhibitors are ongoing, less-invasive intraoperative IDH1 gene profiling might be useful for decision making of the overall treatment strategy of LGGs. Our assay might be a useful tool for precision medicine and surgery of IDH1-mutant gliomas.},
 pages = {91--97},
 title = {A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma},
 volume = {34},
 year = {2017}
}